Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus FLOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus FLOVENT.
DEXASPORIN vs FLOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Fluticasone propionate is a synthetic corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory transcription factors (e.g., NF-κB) and increased synthesis of lipocortin-1, which reduces phospholipase A2 activity and subsequent release of arachidonic acid metabolites (prostaglandins, leukotrienes). In the lungs, it decreases airway inflammation by reducing eosinophil infiltration, mast cell degranulation, and cytokine release.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Inhalation aerosol: 88-880 mcg twice daily; typical starting dose: 88 mcg twice daily. Max: 880 mcg twice daily. Oral inhalation powder: 100-1000 mcg twice daily; typical starting: 100 mcg twice daily. Max: 1000 mcg twice daily.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Approximately 14.4 hours (range 7.8–24.6 hours) for the inhaled route; supports twice-daily dosing; prolonged in hepatic impairment.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Primarily hepatic metabolism (CYP3A4) with fecal excretion of metabolites; renal excretion accounts for <5% of the dose as unchanged drug and metabolites combined.
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid